Lifeboat Foundation

Antibiotic-resistant bacteria are increasingly the source of deadly infections. A team of scientists from the Technical University of Munich (TUM) and the Helmholtz Center for Infection Research (HZI) in Braunschweig have now modified an approved cancer drug to develop an active agent against multidrug-resistant pathogens.

The methicillin-resistant Staphylococcus aureus (MRSA) is the source of severe and persistent infections. Some strains are even resistant to multiple antibiotics. There is consequently an urgent need for new drugs effective against MRSA infections.

“The industrial development of new antibiotics is stalling and not keeping pace with the spread of antibiotic resistance. We urgently need innovative approaches to meet the need for new infection therapies that do not lead directly to renewed resistance,” says Prof. Eva Medina, director of the HZI Infection Immunology Research Group.

Discover the latest features and innovations available in the 65 inches Class Q900 QLED Smart 8K UHD TV (2019). Find the perfect TVs for you!

Yoshua Bengio is known as one of the “three musketeers” of deep learning, the type of artificial intelligence (AI) that dominates the field today.

Bengio, a professor at the University of Montreal, is credited with making key breakthroughs in the use of neural networks — and just as importantly, with persevering with the work through the long cold AI winter of the late 1980s and the 1990s, when most people thought that neural networks were a dead end.

He was rewarded for his perseverance in 2018, when he and his fellow musketeers (Geoffrey Hinton and Yann LeCun) won the Turing Award, which is often called the Nobel Prize of computing.

Mount Sinai researchers have designed an innovative experimental therapy that may be able to stop the growth of triple-negative breast cancer, the deadliest type of breast cancer, which has few effective treatment options, according to a study published in Nature Chemical Biology in December.

The therapy is known is MS1943. In a cancer cell line and mouse models, it degraded a protein called EZH2 that drives the growth of triple-negative breast cancer.

Research teams led by Jian Jin, Ph.D., Director of the Mount Sinai Center for Therapeutics Discovery, and Ramon Parsons, MD, Ph.D., Director of The Tisch Cancer Institute at Mount Sinai, developed MS1943 as a first-in-class small-molecule agent that selectively degrades EZH2. They also showed that agents that inhibit the enzymatic activity of EZH2 but do not degrade EZH2 did not work in triple-negative breast cancer.

Superpowerful lasers for next-generation technologies are closer to existence.

Millions of people need new corneas. In a major breakthrough, researchers can now 3D print them.

The innovative technology used to settle on the Red Planet will prove to be very useful on our own homeworld.

Scientists have discovered yet another life-giving treatment for disease using adult stem cells, while the number of substantial medical breakthroughs from life-taking embryonic stem cell research remains essentially zero.

Neuromyelitis optica (NMO), also known as Devic’s disease, causes the immune system to react against the body’s own cells in the central nervous system, particularly the eyes and spinal cord. Those who contract the disease usually lose their eyesight and ability to walk within five years.

Continue reading “Another adult stem cell breakthrough” »